Implications of integrase inhibitors for HIV-infected transplantation recipients: Raltegravir and dolutegravir (S/GSK 1349572)

BioScience Trends

Volumn 5, Issue 5, 2011, Pages 189-191

  Waki, Kayo ^a,b   Sugawara, Yasuhiko ^c  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug drug interaction (DDI); Highly active antiretroviral therapy (HAART); Kidney transplantation; Liver transplantation

Indexed keywords

2 PYRROLIDONE DERIVATIVE; CALCINEURIN; DOLUTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; RALTEGRAVIR;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; TRANSPLANTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALCINEURIN; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; INTEGRASE INHIBITORS; PYRROLIDINONES; TRANSPLANTATION;

EID: 84857517398     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2011.v5.5.189     Document Type: Article

References (18)

1. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation. 2006; 81:1658-1661
2. Trullas JC, Cofan F, Tuset M, Ricart MJ, Brunet M, Cervera C, Manzardo C, López-Dieguez M, Oppenheimer F, Moreno A, Campistol JM, Miro JM. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011; 79:825-842.
3. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008; 198:1337-1344.
4. Nguyen BY, Isaacs RD, Teppler H, et al. Raltegravir: The first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci. 2011; 1222:83-89.
5. Lenz JC, Rockstroh JK. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: Promises and challenges. Expert Opin Investig Drugs. 2011; 20:537-548.
6. Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, Koike K. Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a single center. Transplantation. 2011; 91:1261-1264.
7. Moreno A, Pérez-Elías MJ, Casado JL, Fortún J, Bárcena R, Quereda C, Del Campo S, Gutiérrez C, Pastor O, Nuño J, Fernandez A, Moreno S. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virusinfected patients after solid organ transplantation. Liver Transpl. 2010; 16:530-532.
8. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009; 9:1946-1952.
9. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a nextgeneration HIV integrase inhibitor. Antimicrob Agents Chemother. 2011; 55:813-821.
10. Min S, Carrod A, Curtis L, Stainsby C, Brothers C, Yeo J, Nichols G. Safety profile of dolutegravir (DTG, S/GSK1349572), in combination with other antiretroviralsin antiretroviral (ART)-naïve and ART-experienced adults from phase IIb studies. [abstract No TUPE238]. 6th International AIDS Society (IAS) conference on HIV pathogenesis,treatment, and prevention; 2011.
11. Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli S. An Open Label, Placebo-Controlled Study to Evaluate the Effect of Dolutegravir (DTG, S/GSK1349572) on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects. [abstract A1-1728]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011.
12. Doesch AO, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Dengler TJ, Ehlermann P, Zugck C, De Geest S, Katus HA. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: A pre-experimental study. Transplant Proc. 2010; 42:4238-4242.
13. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008; 22:1382-1384.
14. Dori L, Buonomini AR, Viscione M, Sarmati L, Andreoni M. A case of rhabdomiolysis associated with raltegravir use. AIDS. 2010; 24:473-475.
15. Masiá M, Enríquez R, Sirvent A, Gutiérrez F. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect. 2010; 61:189-190.
16. Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S. Severe raltegravir-associated rhabdomyolysis: A case report and review of the literature. Int J STD AIDS. 2010; 21:783-785.
17. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011; 83:1443-1451.
18. Moreno A, Fortún J, Graus J, Rodriguez-Gandía MA, Quereda C, Pérez-Elías MJ, Nuño J, Wikman P, Moreno S, Bárcena R. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl. 2011; 17:331-333.